

Edgar Filing: ENDOCYTE INC - Form 8-K

ENDOCYTE INC  
Form 8-K  
March 08, 2013

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): March  
5,2013

Endocyte, Inc.

---

(Exact name of registrant as specified in its charter)

Delaware                      001-35050                      35-1969-140  
(State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.)

3000 Kent Avenue, Suite A1-100, West Lafayette, Indiana 47906  
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: 765-463-7175

Not Applicable

---

Former name or former address, if changed since last report

Edgar Filing: ENDOCYTE INC - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On March 5, 2013, Douglas G. Bailey notified the Company that he would retire from the Company's Board of Directors effective as of the Company's 2013 annual meeting of stockholders. Mr. Bailey's retirement is related to the Company's ongoing succession plan for Board renewal and is not the result of any disagreement with the Company, its management or the Board of Directors.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Endocyte, Inc.

*March 8, 2013 By: /s/ Michael A. Sherman*

*Name: Michael A. Sherman  
Title: Chief Financial Officer*